Healthcare: reloaded...

Antimicrobial touch surfaces have been introduced in healthcare settings with the aim of supporting existing hygiene procedures, and to help combat the increasing threat of antimicrobial resistance. However, concerns have been raised over the potential selection pressure exerted by such surfaces, which may drive the evolution and spread of antimicrobial resistance. This review highlights studies that indicate risks associated with resistance on antimicrobial surfaces by different processes, including evolution by de-novo mutation and horizontal gene transfer, and species sorting of inherently resistant bacteria dispersed on to antimicrobial surfaces.

Nowadays, due to the growing problem of antibiotic resistance, the development of novel anti-ARB therapeutic strategies has been of great interest. Although certain strategies discussed in this review have shown promising potential in clinical or preclinical studies, the complexity of their structure and physiology may protect bacteria from single treatments. The combination of these strategies and flexibility in their use could hold more promise for future anti-ARB treatments. For instance, in order for the antibody–antibiotic conjugate (DSTA4637S) to kill intracellular reservoirs of S. aureus, the binding of the antibody to S. aureus is required.

La protéine CD31 présente à la surface des cellules immunitaires est fortement impliquée dans l’apparition des maladies auto-immunes à en croire une étude Inserm. Sa perte déclencherait la maladie et, à l’inverse, la remplacer constituerait un remède.

It might be possible to effectively cure the most common form of asthma by using genetically engineered cells to kill off the rogue immune cells that trigger asthma attacks, a study in mice suggests. But making this kind of treatment affordable will be a major challenge, and its risks mean it would probably be given only to those who get life-threatening asthma attacks. “For most asthma patients, an inhaler is probably enough, however, approximately 250,000 people die from severe asthma annually,” says Min Peng at Tsinghua University in Beijing, China. “[This] could be an option for those patients.”

Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable; however, designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated drug product for targeting CD33+ tumors called dimerizaing agent–regulated immunoreceptor complex (DARIC33). T cell products demonstrated target-specific and rapamycin-dependent cytokine release, transcriptional responses, cytotoxicity, and in vivo antileukemic activity in the presence of as little as 1 nM rapamycin. Rapamycin withdrawal paused DARIC33-stimulated T cell effector functions, which were restored following reexposure to rapamycin, demonstrating reversible effector function control.

The promising findings, reported in Science Advances, involve CAR-T cell therapy, which supercharges the immune system to identify and attack cancer cells. The paper is titled "TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors."

La chronicisation des maladies représente un défi pour la médecine du XXIe siècle. L’augmentation du nombre de patients atteints d’une affection chronique rend incontournable une réflexion sur l’enjeu social et économique que constitue leur prise en charge.

Si des études ont déjà souligné l'influence de l'épigénétique dans le développement de tumeurs, c'est la première fois qu'il est démontré que les mutations de l’ADN - qui s'accumulent au niveau du génome - ne sont pas indispensables à l'apparition des cancers. En d'autres termes, cette découverte montre que des processus pas forcément génétiques sont entièrement capables de provoquer l'apparition et le développement de tumeur, ouvrant ainsi la voie à de nouvelles pistes thérapeutiques.

Le Groupe de direction mondial sur la résistance aux antimicrobiens – antibiotiques notamment – appelle les Etats membres de l’ONU à réagir urgemment face à cette menace croissante. Sa dernière étude laisse envisager un coût humain et économique vertigineux si des mesures fortes ne sont pas rapidement prises contre la résistance aux antimicrobiens.

Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle with a new analysis presented at the American Association for Cancer Research annual meeting showing that patients may need a higher dose of lymphodepletion than those with blood cancers.

In June, the FDA released a warning about the new antiobesity medications, stating it had received reports of adverse events after people self-administered semaglutide from a compounding pharmacy. The warning also states that compounding pharmacies may be selling salt forms of the active ingredient, including semaglutide sodium and semaglutide acetate, though the FDA is not aware of any basis for compounding a drug using semaglutide salts that would meet federal requirements.

A paradigm change in the understanding of Alzheimer’s pathogenesis has been made evident by recent research, highlighting the significance of concentrating on the soluble oligomeric form of the pathogenic amyloid beta (A-beta) protein to target its early-stage aggregation.

Online directory of strategies and action plans on antimicrobial resistance, published by countries and organisations

The trial, which will take place at Kyoto University Hospital from September to August 2025, will treat 30 males aged 30-64 who are missing at least one molar. The intravenous treatment will be tested for its efficacy on human dentition, after it successfully grew new teeth in ferret and mouse models with no significant side effects.

CAR-T cell therapies have boomed in the past few years since the first FDA approval of this revolutionary new way of treating blood cancer back in 2017, but, while the technology has sped through, cancer doctors are feeling a little left behind. That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical Oncology (ASCO) cancer congress abstracts drop, which asked 100 CAR-T oncologists about how well they felt informed about cell therapies.

The eight constituents of TwX include vitamin C, L-glutamine, niacin, L-cystine, coenzyme Q10, vitamin B2, succinic acid, and fumaric acid. The combined antioxidant effect is likely more potent than the activity of either compound alone. Previous studies have demonstrated improvement in cognition, memory, and motor coordination in mouse models of dementia, and reduction in affected region size, oxidative stress, and inflammation in mouse models of ischemic stroke following treatment with TwX.

At a joint event held by the Friends of Cancer Research and Parker Institute for Cancer Immunotherapy on Monday, cell therapy pioneer Carl June of the University of Pennsylvania Perelman School of Medicine revealed findings from a recent unpublished study from his group that looked at 783 patients who had received CAR-T treatments for HIV-1 or various cancers. Over more than 2,200 patient-years of observation, the group found 18 patients, or 2.3%, who developed secondary malignancies.

Alopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.

Carmat ambitionne de répondre à un enjeu majeur de santé publique lié aux maladies cardiovasculaires, l’insuffisance cardiaque, qui représente la première cause de décès dans le monde. Plus précisément, Carmat vise à apporter une solution durable au traitement de l’insuffisance cardiaque terminale, maladie pour laquelle il existe aujourd’hui très peu d’options efficaces, la principale étant la transplantation cardiaque.

Today’s hypodermic needles are hollow devices made from flat sheets of stainless steel heated to achieve pliability. Fabrication then occurs by rolling stainless steel strips into a tubular shape and using a laser to weld the two seams.

Instead of waiting anywhere from 30 minutes to several hours for infusions into their veins, patients would spend just a few minutes being injected under the loose skin of their abdomens or thighs. Clinicians would save time and money, and patients would leave the clinic much sooner than normal. The ease of subcutaneous injections also opens up an opportunity for home treatment, a potential boon for people who don't want to spend their remaining time on hospital visits.

The expanded indication permits treatment with the chimeric antigen receptor T cells after first relapse and applies to adults who are refractory to lenalidomide and have received at least one previous line of therapy, including a proteasome inhibitor and an immunomodulatory agent.

Health experts urge women not to use Ozempic or similar drugs to increase fertility, due to increased risks of birth defects and miscarriage.